Genomic alterations and phenotype of large compared to small high-grade ductal carcinoma in situ
- PMID: 21496874
- DOI: 10.1016/j.humpath.2011.01.002
Genomic alterations and phenotype of large compared to small high-grade ductal carcinoma in situ
Abstract
A clinically distinct subgroup of pure ductal carcinoma in situ presents as an extensive, high-grade lesion, which nevertheless lacks invasion. We sought to evaluate differences between those ductal carcinomas in situ presenting as large versus small lesions while controlling for high-grade, to determine whether there exist phenotypic and genetic differences between the 2 groups. Fifty-two cases of pure high-grade ductal carcinomas in situ were collected retrospectively, consisting of 27 large (>40 mm) and 25 small (<15 mm) cases. The 2 groups were compared based on genomic copy number assessed by array-based comparative genomic hybridization and by phenotype determined by immunohistochemistry for estrogen receptor, progesterone receptor, Ki-67, p53, cyclin D1, p16, cyclooxygenase 2, human epidermal growth factor receptor 2, and CD68. Large lesions presented at a younger age, with lower incidence of comedonecrosis and periductal macrophage response. Larger lesions also had significantly lower estrogen receptor expression, lower cyclin D1 expression, and lower Ki-67 index. The subset of 9 large palpable tumors had significantly lower p16/cyclooxygenase 2 expression and lower Ki-67 index compared to nonpalpable tumors. Genomically, larger lesions had fewer break points, fewer amplifications, and decreased copy number gains involving chromosome 8q and chromosome 20q when compared to the small lesions. Among pure high-grade tumors, small and large groups show specific genomic and phenotypic differences. Interestingly, larger tumors showed some molecular features associated with better prognosis. A more thorough evaluation of these differences could help identify the likelihood of recurrence or progression for in situ lesions.
Copyright © 2011 Elsevier Inc. All rights reserved.
Similar articles
-
Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma.Am J Surg Pathol. 2009 Apr;33(4):496-504. doi: 10.1097/PAS.0b013e31818af361. Am J Surg Pathol. 2009. PMID: 19047897
-
The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/multicentric invasive ductal carcinoma of breast.Hum Pathol. 2012 Jan;43(1):48-55. doi: 10.1016/j.humpath.2010.08.026. Epub 2011 Jul 5. Hum Pathol. 2012. PMID: 21733550
-
Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.Mod Pathol. 1994 Feb;7(2):257-62. Mod Pathol. 1994. PMID: 7911998
-
Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.APMIS Suppl. 2003;(108):1-67. APMIS Suppl. 2003. PMID: 12874968 Review.
-
Molecular evolutionary patterns in breast cancer.Adv Anat Pathol. 2003 Sep;10(5):278-90. doi: 10.1097/00125480-200309000-00003. Adv Anat Pathol. 2003. PMID: 12973049 Review.
Cited by
-
Genome evolution in ductal carcinoma in situ: invasion of the clones.J Pathol. 2017 Jan;241(2):208-218. doi: 10.1002/path.4840. Epub 2016 Nov 27. J Pathol. 2017. PMID: 27861897 Free PMC article. Review.
-
Copy number analysis of ductal carcinoma in situ with and without recurrence.Mod Pathol. 2015 Sep;28(9):1174-84. doi: 10.1038/modpathol.2015.75. Epub 2015 Jun 19. Mod Pathol. 2015. PMID: 26321097
-
Large palpable ductal carcinoma in situ is Her-2 positive with high nuclear grade.Int J Clin Exp Pathol. 2015 Apr 1;8(4):3963-70. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26097582 Free PMC article.
-
Genomic landscape of ductal carcinoma in situ and association with progression.Breast Cancer Res Treat. 2019 Nov;178(2):307-316. doi: 10.1007/s10549-019-05401-x. Epub 2019 Aug 17. Breast Cancer Res Treat. 2019. PMID: 31420779 Free PMC article.
-
Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast.Breast Cancer Res. 2015 Jun 16;17(1):80. doi: 10.1186/s13058-015-0586-z. Breast Cancer Res. 2015. PMID: 26078038 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous